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Background
A phase I/II HIV vaccine trial (HIVIS 03) employing a
multiclade, multigene HIV-1 DNA prime/MVA boost vac-
cine among healthy volunteers is ongoing in Dar es
Salaam, Tanzania.
Methods
Sixty healthy HIV negative volunteers including 15
females, were randomised to 3 groups and were injected
at months 0, 1 and 3 with plasmid DNA vaccine (pro-
duced by KI/SMI and Vecura, Sweden) containing gp160
of HIV-1 subtypes A, B, C; rev B; p17/p24 gag A, B and
Rtmut B, at 1 mg i.d. (n = 20) or 3.8 mg i.m. (n = 20) or
placebo (n = 20) using the Biojector. At month 9, a single
i.m. injection with MVA 108 pfu of MVA/CMDR express-
ing HIV-1 genes env, gag, pol of CRF01A_E (produced by
NIAID and WRAIR, USA) or placebo was administered. T-
lymphocyte proliferative (TLP) responses to AT-2 inacti-
vated HIV-1 antigen from virus isolates/clade MN/B,
KNH1144/A, TZA125/C and CM235/A_E were tested by a
standard 3H-thymidine uptake assay. TLP was reported as
stimulation index (SI) and SI above 6 was considered pos-
itive based on mean reactivity at baseline in 40 volunteers.
Results
Two weeks after the 3rd DNA/placebo injection, 24 of 52
(46%) volunteers had positive TLP responses. Two weeks
and two months after the HIV-MVA/placebo boost, 35 of
48 (73%) and 32 of 44 (73%) volunteers had positive TLP
responses, respectively. Thus far, 33 volunteers have been
tested six months after the HIV-MVA/placebo boost and
20 (61%) have positive TLP responses. There was a high
degree of cross reactivity as shown by strong proliferative
responses to all four isolates tested. The TLP responses
were sustained and 6 months after the HIV-MVA boost the
greatest reactivity was seen against CM235/A_E. The study
remains blinded.
Conclusion
HIVIS03 DNA-MVA vaccine has so far demonstrated
strong HIV-specific T-lymphocyte proliferative responses
with a high degree of cross clade reactivity.
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